Cellular Rejuvenation

In 2006 Takahashi and Yamanaka showed that four transcription factors — Oct4, Sox2, Klf4 and Myc — could return an adult mouse fibroblast to a pluripotent state. Reprogramming erases what a cell is. It also, apparently incidentally, erases how old the cell is. Partial reprogramming is the proposal that you can run that process briefly, keep the age reset, and stop before the identity goes. Established The framing under test in this brief is the strong version of that claim: cellular age is resettable in a living adult without loss of cellular identity.

Established The measured effects are real and reproducible in at least three laboratories, and they are mostly molecular. Cyclic induction of the four factors ameliorates age-associated markers in progeroid mice; three factors without Myc restore vision in a mouse glaucoma model; thirteen days of transient reprogramming moves cultured human fibroblasts about thirty years on an epigenetic clock while they reacquire fibroblast identity. Frontier The claimed effect, in coverage and in fundraising, is lifespan reversal. The bridge between the two is one unresolved question: whether epigenetic age and biological age are the same thing.

Established This is also the most heavily capitalised subject in the longevity cluster. Altos Labs launched on 19 January 2022 with US$3 billion in a single round. Established Against that, the field's only lifespan result in normally-ageing mice is a 7% extension of total median lifespan, and its strongest human datapoint is three fibroblast donors in a dish with telomeres unchanged. Speculative That gap is not evidence the science is wrong. It is evidence that the risk in this field is concentrated entirely in translation, and that the endpoint everybody reports has never been validated against the outcome anybody wants.

Established The founding in vivo result established both the effect and its safety limit in the same paper. Ocampo, Reddy, Martinez-Redondo and colleagues, in Cell in 2016, induced OSKM in mice carrying a doxycycline-inducible cassette using a cyclic protocol: two days on, five days off, repeated. In LAKI progeroid animals this produced what the paper calls a dramatic increase in median and maximal lifespan against untreated LAKI controls. Established The same work reports that continuous doxycycline caused significant weight loss and high mortality after four days, attributed to dedifferentiation in vital organs, and that the cyclic schedule eliminated that mortality entirely. Established Mice carrying two copies of the OSKM cassette on cyclic dosing for eight weeks developed teratomas in liver, kidney and pancreas; single-copy mice developed none. Tumorigenesis is dose-dependent and the therapeutic window is narrow — that is the central safety fact of the field, and it was in the first paper.

Established The cleanest functional result in the field is not about ageing at all; it is about an eye. Lu, Brommer, Tian and colleagues, in Nature in 2020, expressed Oct4, Sox2 and Klf4 — OSK, with Myc deliberately omitted — in mouse retinal ganglion cells. The reported outcome is restoration of youthful DNA methylation patterns and transcriptomes, axon regeneration after optic nerve crush, and reversal of vision loss both in a glaucoma model and in aged mice. Established The effect requires the DNA demethylases TET1 and TET2, which makes it a mechanistic claim rather than a phenotypic one: the restoration is an active demethylation process, not a generic wipe. Frontier The authors' interpretation is the field's animating hypothesis in one sentence — that mammalian tissues retain a record of youthful epigenetic information that can be accessed to improve tissue function in vivo. Speculative Whether a “record” in that sense exists, or whether the phrase is a metaphor for a robust attractor state, is not settled by the experiment.

Established The best long-duration experiment in normally-ageing mice reports no lifespan result, and is routinely cited as though it did. Browder, Reddy, Yamamoto and colleagues, in Nature Aging in 2022, ran two regimens in wild-type animals — seven months of treatment from 15 months of age, and ten months from 12 months, both ending at 22 months. Established The reported outcomes are reversion of the epigenetic clock and reduced expression of genes involved in inflammation, senescence and stress response, together with the authors' claims that partial reprogramming protocols can be designed to be safe and effective in preventing age-related physiological changes, and that longer regimens outperform shorter ones. Established The paper contains no lifespan endpoint. A duration claim and a safety claim are not a longevity claim, and the difference matters because this is the only long-run wild-type dataset the field has. Frontier Read for what it does contain rather than what it does not, it is the strongest evidence available that months of intermittent induction can be tolerated at all — which is the prerequisite for everything else and was not obvious after the four-day deaths of 2016.

Established The strongest human result is thirty years of rejuvenation in three people's cells, in a dish, with the telomeres unmoved. Gill, Parry, Santos and colleagues at the Babraham Institute, in eLife in 2022, used maturation-phase transient reprogramming (MPTR) — thirteen days of doxycycline, with 10, 13, 15 and 17 days tested. Donors: three, chronologically 38, 53 and 53 years old; epigenetically 45, 49 and 55. Established Result: approximately 30 years of rejuvenation on the multi-tissue epigenetic clock, with the transcriptome rejuvenated by a comparable margin on a new transcriptome clock, and the cells reacquiring fibroblast morphology, transcription and epigenetics — identity returned, which is the load-bearing part. Established The authors' own caveats are unusually candid: the Yamanaka factors possess oncogenic properties, and they cannot exclude that a minor subset of cells retained pluripotent-like characteristics. Established Telomeres did not lengthen. Frontier One laboratory, three donors, three biological replicates. Everything the public hears about human rejuvenation traces to this experiment.

Established The instrument the whole field reports on was built to predict chronological age, and it does that very well. Horvath's 2013 clock in Genome Biology uses 353 CpG sites under elastic-net regression, trained on 7,844 non-cancer samples across 51 healthy tissues and cell types from 82 datasets, achieving correlation 0.96 with chronological age in test data and a median error of 3.6 years. Established Horvath's own reading is that DNA methylation age measures the cumulative effect of an epigenetic maintenance system, and he states explicitly that it does not measure mitotic age or cellular senescence — it tracks chronological age accurately even in non-proliferative tissue such as brain. Frontier The field's own 2024 review says the obvious thing out loud. Yucel and Gladyshev, in Nature Communications, write that epigenetic clock reversal and rejuvenation should not be used interchangeably, because the causal relationship between them is yet to be determined. Frontier Since almost every reprogramming result in the literature is reported as a clock reversal, this is a challenge to the interpretation of essentially the entire field, made from inside it.

Established Safety is tissue-dependent in a way that reorganises the whole engineering problem. The same review records that continuous OSK expression in retina caused no teratomas even after 10 to 18 months, while continuous expression of Yamanaka factors can produce liver and intestinal failure in mice — with about 60% of mice surviving a month of continuous OSKM when intestinal and hepatic expression was excluded. Established Post-mitotic tissue tolerates prolonged expression; proliferative tissue does not. Frontier And the one in vivo lifespan experiment in normally-ageing mice reports a modest number honestly and is quoted dishonestly. Macip, Hasan, Hoznek and colleagues delivered AAV9.TRE3-OSK plus an AAV9 rtTA vector retro-orbitally to 124-week-old wild-type C57BL/6J mice and reported a 109% increase in median remaining life: controls 8.86 weeks remaining, treated 18.5 weeks. Established Total median lifespan moves from about 133 weeks to about 142.5 — an absolute gain of roughly 9.5 weeks, about 7%. No teratomas were observed; the authors state that thorough monitoring studies in large animals will be required; the lifespan cohort's sample size is not stated in the preprint. Frontier For calibration, a single dose of AAV9-mTERT telomerase gene therapy in 2012 reported +24% median lifespan when given at one year and +13% at two years, both against total lifespan and with no excess cancer — a smaller headline, a larger real effect, and a paper nobody misquotes.

Established A methylation reset is a reset of one hallmark, and the record contains no claim that it is more than that. Epigenetic alteration is one entry in the standard twelve-hallmark framework, alongside genomic instability, telomere attrition, mitochondrial dysfunction, stem-cell exhaustion and the rest. Frontier Nothing in the reprogramming literature reports repair of accumulated somatic mutations, and the human result is explicit that telomeres did not lengthen — so at least two axes of ageing are demonstrably untouched by an intervention that moved a clock thirty years. Speculative The optimistic reading is that epigenetic state is upstream of the others, so restoring it restores the cell's ability to maintain itself and the rest follows. Frontier That is a hypothesis with a mechanism sketch and no direct test: no published experiment shows a downstream hallmark improving because an upstream methylation state was restored. Established The cell that has been reprogrammed still carries every mutation it acquired, and a mutated genome read by a youthful epigenome is not obviously a young cell.

Frontier The identity half of the claim is better evidenced in a dish than in an animal, which is the wrong way round. In culture, identity retention is measured: the Babraham fibroblasts reacquired fibroblast morphology, fibroblast transcription and fibroblast methylation, and that is the strongest single piece of evidence that a partial reset is possible at all. Frontier In vivo, identity retention is inferred — almost always from the absence of teratomas, which is a proxy for the extreme failure and says nothing about a cell that has drifted slightly and is still doing its job badly. Established The mechanism of the acute deaths in the first paper was dedifferentiation in vital organs, meaning the animals died of exactly the identity loss the proxy does not measure. Speculative A functional-identity endpoint — tissue-specific output measured during treatment rather than after — would settle it, and is missing from every published in vivo protocol. Declaring the tie honestly: the reset is demonstrated, the identity is demonstrated, and their coexistence is demonstrated only in cultured fibroblasts from three people.

Frontier The field's own list of open questions is the best available map of the frontier, and it is short. The 2024 Yucel and Gladyshev review names five: whether pluripotency networks are necessary for rejuvenation or separable from it; whether genomic loci contribute differentially, making selective rejuvenation possible; how long effects persist after treatment ends; which individual factors drive rejuvenation rather than reprogramming efficiency; and whether safety profiles are tissue-specific. Frontier Not one of those has an answer in the published record.

Frontier The single deepest question is whether the clocks measure ageing or merely correlate with it. The Horvath clock is a regression fit against chronological age; nothing about a regression guarantees that moving the predictor moves the predicted quantity. Frontier The concrete instance of dissociation is already published: in the Babraham human-cell work the clock moved thirty years while telomeres did not move at all. Frontier A second instance runs the other way — a 19-participant human senolytic cohort taking dasatinib and quercetin for six months showed increased epigenetic age acceleration on earlier-generation clocks and decreased telomere length, an intervention the field believes is beneficial moving the clock the wrong way. Speculative Both results are compatible with the clocks reading a real biological quantity that is only one of several; both are also compatible with the clocks reading a methylation drift process that is a marker of elapsed time and not a cause of anything.

Speculative The mechanistic keystone of the optimistic reading is the information-loss hypothesis, and this brief cannot source it directly. The claim, associated with the ICE-mouse work published in Cell in 2023, is that ageing is driven by loss of epigenetic information rather than by damage accumulation, that inducing non-mutagenic DNA double-strand breaks accelerates epigenetic ageing, and that OSK partly reverses it. Handwave The primary text could not be retrieved for this brief and no number from it is printed here. The hypothesis is named because it is what the whole programme rests on: if ageing is information loss and a backup copy persists, rejuvenation is a read operation. If ageing is damage, resetting the methylome leaves the damage in place.

Frontier Chemical reprogramming would remove the field's biggest translational obstacle and is currently entirely in vitro. A 2023 screen of about 80 molecular combinations, derived from two chemically-induced-pluripotency cocktails, identified six validated cocktails that reversed senescence markers, assayed with a nucleocytoplasmic compartmentalisation reporter and transcriptomic clocks. Established There are no animal lifespan studies in the paper; every experiment is in a dish, the primary readout is a proprietary reporter, the authors state that safety must be tested rigorously in mammalian models before human trials, and the disclosure lists consulting roles, board seats, investments and a provisional patent. Frontier No independent replication of those cocktails was found in preparing this brief. It is nonetheless the most important direction in the field, because a doxycycline-inducible transgenic cassette is not a therapy and never will be.

Frontier Nobody has published a time-to-reversion curve. How long a rejuvenation effect persists after treatment stops is on the field's own open-questions list, and the absence is structural rather than accidental: measuring durability requires following animals long after the exciting result, which is exactly the experiment nobody's funding round depends on. Speculative If effects decay on a timescale of weeks, partial reprogramming is a chronic therapy with a chronic therapy's cumulative oncogenic risk. If they persist for a substantial fraction of remaining life, it is an intervention. These are different products and the literature cannot presently distinguish them.

Speculative The sharpest sceptical reading of the human result is that it is a culture artefact. Fibroblasts in culture are already under selection; a thirteen-day perturbation followed by measurement of a 353-CpG regression may be reporting on which cells survived rather than what happened inside them. Frontier The authors themselves raise the adjacent worry about residual pluripotent-like cells. Speculative The discriminating measurement is single-cell resolution showing the methylome shift within individual cells rather than across the population, and it has not been published. Handwave Until it is, “thirty years younger” is a statement about a population average in a flask.

Frontier The binding bottleneck in this field is conceptual, not technical, and no amount of capital touches it. The field measures its success with an instrument whose validity for that purpose its own leading reviewers say is undetermined. Until clock deltas are shown to predict functional deltas, every result is uninterpretable in the direction that matters — a paper reporting a large clock reversal and no functional endpoint has demonstrated that reprogramming changes methylation, which nobody doubted.

Established The second bottleneck is delivery, and it is industrial. Because retina tolerates 10 to 18 months of continuous OSK while liver and intestine fail, a therapy is not “reprogramming” but a tissue-by-tissue programme of vectors, promoters, doses and schedules. Frontier The published in vivo work uses a two-vector AAV9 system with a doxycycline-inducible transactivator delivered retro-orbitally into a transgenic-friendly mouse; scaling that to a human requires tissue-restricted expression, controllable dose, a genuine off-switch, and manufacturing at doses no rejuvenation programme has attempted. Speculative On present evidence the constraint on a first therapy is vector engineering rather than reprogramming biology.

Established The third is the transgene itself. Every in vivo result in the record depends on a genetically encoded inducible cassette or an AAV delivering one. Frontier Chemical or mRNA reprogramming removes that, and has been demonstrated only in cell culture.

Frontier The fourth is durability — no published decay curve — and the fifth is that no properly powered lifespan study of a reprogramming intervention exists in genetically heterogeneous mice. Established The apparatus to run one exists: the NIA Interventions Testing Program has operated since 2002 across three sites in UM-HET3 mice with 80% power to detect a 10% lifespan increase, and accepts up to six agents a year by open nomination. Speculative It has never been pointed at a reprogramming intervention. That is a choice, not a limitation, and it is the cheapest available correction to the entire evidence base.

Frontier The sixth is measurement, and it is quietly expensive. The decisive experiments in this subject are longitudinal and within-individual: the same cells, the same animal, before and after. Speculative That requires single-cell methylome assays at a price that permits repeated sampling, and a standard functional battery that different laboratories actually share, so that a clock delta in one paper can be set against a grip-strength delta in another. Frontier Neither exists. Established The consequence is that the field's results are cross-sectional comparisons of treated and untreated groups scored on a population average — which is the design least able to answer the question the field is actually asking.

Frontier This brief waits on results other people are producing. The first is endpoint validation, which belongs as much to Longevity Therapies as here: a prospective test of whether epigenetic-clock deltas predict within-individual morbidity and mortality, using biobank data that already exist. Established No reprogramming result becomes interpretable until that is answered, and no reprogramming laboratory is positioned to answer it.

Established The second is delivery. Tissue-restricted, dose-controllable, switchable expression in a large animal is the same capability that Genetic Engineering and Precision Medicine need for every other in vivo gene therapy, and reprogramming is a harder case than most because the payload is oncogenic at the wrong dose. Speculative Progress here will arrive from outside this field.

Frontier The third is single-cell methylome measurement at a cost that allows longitudinal within-individual designs; the fourth is a defined clinical indication with a regulator-accepted endpoint, which the retinal work already supplies and the ageing framing does not. Established The fifth is the field's own instrument: better clocks trained on mortality rather than on chronological age would change what every published result means. Speculative Adjacent to all of these sits the question Brain Preservation asks from the other end — how much of a person is carried in molecular rather than structural state — which decides whether reprogramming a neuron is safe in principle.

Frontier One dependency runs the other way and is worth naming. If the information-loss hypothesis is right, this field supplies a result the rest of biology needs: evidence that a differentiated cell retains an addressable record of its own earlier state. Speculative That would matter to regeneration, to development and to cancer biology regardless of whether any rejuvenation therapy is ever approved. Handwave It is also the claim with the least direct evidence in the brief, which is why the within-individual methylome comparison is listed first among the experiments and not last.

The workback plan for the currently-impossible version — reversing biological age in a living adult human by a decade or more, safely and durably — is an ordered chain, and the early links are cheap.

Frontier 1. Report a functional endpoint alongside every clock delta, and test whether one predicts the other across studies. Grip strength, wound healing, immune response, cognition, survival. This is a reporting convention, not a technology, and it is the field's foundational gap. Speculative 2. Show that the restored state is the individual's own prior state. Sample the same cell population from an individual before ageing and after reprogramming and ask whether the post-reprogramming methylome matches that individual's earlier methylome more closely than a generic young reference. This experiment is tractable, decisive for the information-loss hypothesis, and appears never to have been done.

Frontier 3. Separate rejuvenation from pluripotency. A screen for factors producing clock and function reversal without inducing pluripotency markers; if none exists, cancer risk is intrinsic and the window stays narrow forever. Frontier 4. Take the transgene out in vivo. Chemical or mRNA reprogramming in an animal, with the same endpoints as the transgenic work. Speculative 5. Publish a time-to-reversion curve — treat, stop, and measure clock and function at intervals until they return to baseline or do not.

Established 6. Run a reprogramming intervention through the Interventions Testing Program in UM-HET3 mice at three sites, with total median and maximum lifespan reported rather than remaining life. Frontier 7. Resolve the culture-artefact objection with single-cell methylome data on the human MPTR protocol. Frontier 8. Repeat the retinal experiment as a clinical programme — cell-type-restricted delivery, a defined disease, a regulator-recognised endpoint. Speculative Link 8 is not blocked by anything scientific and has been available since 2020.

Frontier Which link is actually binding: the first, and it is conceptual rather than technical. Until a clock delta is shown to predict a functional delta, links 3 through 8 are all being scored on an instrument of unknown validity, and a positive result at any of them can be read two ways. Established Links 1, 2 and 5 need no new technology and no new capital of consequence — they are reporting conventions and follow-up measurements. Speculative The second binding link is institutional rather than scientific: the lifespan machine already exists, is publicly funded, takes nominations once a year, and has never been asked. A field with three billion dollars has not spent the price of one ITP slot on the experiment that would tell it whether it is right.

Established Nothing in the published in vivo record is a device that could be built for a person. The standard construct is a doxycycline-responsive OSK or OSKM cassette plus a reverse tetracycline transactivator, either germline-encoded or delivered as two AAV9 vectors retro-orbitally, with dosing controlled by putting an antibiotic in the drinking water. Frontier A human version needs the same four properties the mouse version obtains by construction: cell-type restriction, dose control across a narrow therapeutic window, an off-switch that works faster than a tumour forms, and durable-enough expression to matter.

Established Tissue tolerance is the design specification and it is already quantified. Retina takes 10 to 18 months of continuous OSK without teratomas; liver and intestine fail; excluding hepatic and intestinal expression leaves about 60% of mice surviving a month of continuous OSKM. Speculative That argues for a first product that is local rather than systemic — intravitreal delivery to a post-mitotic tissue behind a blood-tissue barrier, in a compartment clinicians already inject routinely.

Frontier The transgene-free routes each carry an engineering cost. Chemical cocktails avoid vectors entirely but have no in vivo demonstration and no pharmacokinetics. Speculative mRNA-lipid nanoparticle delivery gives transient, dose-metered expression with no genomic footprint, which is the right shape for a pulsed protocol, but requires repeat administration and tissue targeting that current formulations do not achieve outside liver. Established Manufacturing, potency assays and release criteria for a product whose mechanism is partial dedifferentiation have no regulatory precedent. Frontier And every large-animal safety study the field's own authors say is required — monitoring for teratoma formation over years, in animals whose lifespan is measured in decades — is a programme, not an experiment.

Speculative Two requirements have no analogue in existing gene therapy and should be specified now rather than discovered later. The first is surveillance: a treatment whose principal risk is a tumour arising months after dosing needs an imaging and biomarker protocol running for years, which is a cost per patient rather than a cost per programme. Handwave The second is a kill-switch that acts on the transduced cells rather than on the inducing drug — withdrawing doxycycline stops new expression but does not remove a cell that has already crossed toward pluripotency. Frontier Suicide-gene systems exist in cell therapy and have never been combined with a reprogramming payload.

Established The competing rejuvenation modality is subtraction, not reprogramming, and its best experiment is more elegant than anything in this brief. Heterochronic parabiosis — joining the circulations of a young and an old animal — produced the young-plasma industry. Frontier Then Mehdipour and colleagues replaced about half of an old mouse's plasma with saline plus 5% albumin, containing nothing young at all, and reported enhanced muscle repair, reduced hepatic adiposity and fibrosis, and increased hippocampal neurogenesis — outcomes that met or exceeded heterochronic blood sharing. Frontier A companion study in 22 to 24-month-old mice reported improved whisker discrimination and novel object recognition and reduced activated microglia, at n=4 per behavioural group. Frontier The human data are n=8 therapeutic plasma exchange patients aged 60 to 77, uncontrolled and unblinded, scored on a bespoke ten-protein “noise” biomarker developed by the same group rather than on an established clock.

Established Senolytics occupy the adjacent slot and share the field's signature reporting error: the widely quoted 36% figure is a 36% increase in post-treatment survival in mice already 24 to 27 months old. Established Rapamycin, the best-evidenced longevity intervention in mice, is the calibration point — fed from 600 days of age it extended median and maximum lifespan by 14% in females and 9% in males, reported as total lifespan. Speculative Reprogramming has never been compared head to head with any of them under a common protocol. Frontier Further out sit Limb Regeneration and Whole-Organ Regeneration, which want controlled dedifferentiation for a different purpose, and Biological Immortality, which asks whether the whole target is coherent.

Speculative The technologies that would make reprogramming deliverable are not being built by this field. Targeted lipid nanoparticles, cell-type-restricted promoters and controllable expression systems come from vaccine and gene-therapy programmes; Nanomedicine supplies the delivery vehicles and Precision Medicine supplies the stratification that would decide who is dosed. Frontier Meanwhile the epigenetic clock has become an instrument shared by every modality in the cluster, which means a single unresolved validity question sits underneath senolytics, plasma exchange, geroprotectors and reprogramming simultaneously. One measurement error, four fields.

Established The structural fact about this field is a ratio between two numbers. Altos Labs launched on 19 January 2022 with US$3 billion, backed by Yuri Milner through the Breakthrough Foundation vehicle, Jeff Bezos and ARCH Venture Partners, with sites in California, Cambridge and Japan and principal-investigator salaries reported as potentially ten times those at comparable research institutions. Established Meanwhile the field's flagship public trial in the adjacent topic — TAME, over 3,000 participants aged 65 to 79 across 14 institutions — has never started for want of $30 to $50 million, of which about $9 million was contributed by NIH for biomarker work only. Frontier Nir Barzilai's explanation is the most useful sentence in the cluster: those big billionaires want moonshots, and TAME is not a moonshot.

Established Altos's own framing is more careful than its coverage. Its president describes the goal as healthspan, with longevity extension an accidental consequence. Frontier Two other reprogramming-focused companies — Retro Biosciences and NewLimit — are frequently listed alongside it in the same sentence about capital. This brief prints no funding figure for either, because none could be verified against a primary source in preparing it, and the widely repeated numbers travel without one. Established What can be said without a source problem is the output side: no company in this field has published a lifespan result in a normally-ageing mammal, and the one preprint that reports one came from a small group, not from the well-capitalised laboratories.

Established The institutional gap that actually binds is regulatory. Ageing is not a recognised indication, so there is no endpoint, no trial design and no reimbursement pathway — the same constraint that shapes Longevity Therapies and Biological Immortality. Speculative Absent an approved route, an unregulated one appears: the young-plasma clinics of the 2010s are the precedent, and reprogramming has more consumer appeal and worse failure modes. Frontier A standing public lifespan facility that accepted reprogramming nominations, and disclosure rules requiring functional endpoints alongside clock deltas in any marketed claim, would each cost a rounding error against $3 billion.

Established The consent problem here is unusual because the intervention is elective and the risk is delayed. A partial reprogramming therapy would be offered to people who are not ill, carrying a dose-dependent teratoma risk established in the first mouse paper and never characterised in a large animal over years. Frontier Nobody can presently quote a durability figure to a patient, because no time-to-reversion curve exists; a person consenting to a treatment of unknown duration cannot weigh repeat exposure against cumulative oncogenic risk.

Speculative The commercial layer already sells the measurement. Epigenetic age tests are consumer products; the clock they use was trained to predict chronological age with a median error of 3.6 years, and its developer states it does not measure senescence or mitotic age. Handwave A market in which people buy a number, buy an intervention to move the number, and are sold the movement as rejuvenation is a closed loop with no outcome in it. Frontier The enforcement question is therefore not about reprogramming clinics that exist today but about the ones a single positive human result would create in a year.

Speculative The identity question is the one the field does not discuss. Reprogramming works by moving a cell toward a less-differentiated state; in a neuron, differentiated state is not a bystander to function but the substrate of it. Handwave If any part of long-term memory is held in molecular and epigenetic state rather than purely in synaptic structure — a serious minority position in the preservation literature — then an epigenetic reset in the central nervous system is not rejuvenation but erasure, and the endpoint that would detect it has never been included in a study. Speculative A memory-retention assay in a reprogrammed rodent is a straightforward experiment that the field's own protocols could accommodate tomorrow, and its absence from a literature that has run ten-month whole-body regimens is conspicuous.

Frontier The distributional question is the ordinary one and it arrives early here. A therapy delivered by AAV with years of imaging surveillance is expensive by construction, and the first version will be bought rather than reimbursed, because ageing is not an indication and no payer covers a non-indication. Speculative That produces the least defensible distribution: an unproven intervention, available to the wealthy, measured on an endpoint sold by the people selling the treatment.

Speculative The realistic success case is not immortality; it is compression of morbidity in specific tissues. A retinal reprogramming therapy that restored optic nerve function would be a large clinical advance and would change nothing about the shape of a human life. Speculative A general one that added a decade of healthy function would move dependency ratios, pension arithmetic and the age structure of institutions far more than it moved maximum lifespan — the same distinction between healthspan and lifespan that the field's own leadership uses and its coverage discards.

Handwave The exotic case is a full reset in a living adult mammal, and it is not obviously desirable even if achievable. A whole-organism return to a youthful epigenetic state would require simultaneous, dose-controlled, tissue-specific induction in organs with incompatible tolerances, and would run headlong into the one thing every experiment agrees on: cells that forget what they are kill the animal in days. Handwave A civilisation with that capability would have to decide whether a nervous system reset to a younger configuration carries the same person forward, which is a question about identity rather than biology.

Speculative The failure case has its own consequences. If the clocks are a mirage, this field will have absorbed several billion dollars and a generation of the best cell biologists on an endpoint that did not mean what it appeared to, while a $30 million public trial of a generic drug went unfunded for a decade. Frontier That outcome is not unlikely enough to leave out of the planning. Speculative The recoverable value in that case is real but indirect: the delivery systems, the tissue-tolerance map and the demonstration that a differentiated cell can be pushed a long way and come back are useful to regenerative medicine whether or not anyone's biological age falls.

Handwave The largest civilizational consequence may be epistemic rather than biological. This is the clearest live case of a scientific field organised around a proxy measurement that its own reviewers say may not measure what it is used for, funded at a scale that makes correcting the proxy commercially unattractive. Speculative How that resolves — whether the validity study gets run and published, and by whom — is a test of whether privately capitalised science can audit its own endpoints. The result of that test generalises far beyond ageing.

These horizons track the specific results that would have to land, not the field's own announcements.

• 10 yr: Frontier A cell-type-restricted reprogramming therapy in a defined ophthalmic indication reaches human trials; the retinal work has had a regulatory path since 2020 and needs no new biology, only a sponsor willing to sell a treatment for glaucoma rather than for ageing. Frontier In vivo transgene-free reprogramming demonstrated in a mammal, most plausibly by mRNA rather than by the chemical cocktails, which have no pharmacokinetics. Speculative A published time-to-reversion curve, and the first prospective test of whether clock deltas predict within-individual morbidity and mortality in an existing biobank — the two cheapest decisive results in the field, both currently unfunded and neither requiring a new instrument.
• 25 yr: Speculative A reprogramming intervention run through a properly powered genetically heterogeneous mouse lifespan programme with total median and maximum lifespan reported, settling whether the effect is the 7% now in the record or something larger. Speculative Tissue-specific delivery mature enough for a systemic protocol in a large animal, with years of tumour surveillance attached. Frontier A regulator-accepted surrogate endpoint for age-related decline, most plausibly borrowed from an organ-specific indication rather than granted for ageing as such. Handwave A first answer to whether the restored state is the individual's own prior state or a generic young-like one.
• 50 yr: Speculative If and only if clock reversal is shown to track function, a chronic or repeated partial-reprogramming regimen in humans with a measured effect on age-related disease incidence rather than on a methylation score. Handwave Selective locus-level rejuvenation — resetting some epigenetic marks and deliberately not others — which the field lists as an open question and which nobody can currently attempt, since no method addresses individual loci at scale in a living animal. Speculative Alternatively, and just as plausibly on present evidence, a settled negative: clocks shown to be markers rather than levers, and the modality retired to regenerative medicine where its functional results already are.
• 100 / 250+ yr: Handwave A whole-organism reset in a living adult mammal, with tissue-by-tissue dose control and a working off-switch, is the version this subject is famous for and there is no current path to it — the tolerances of retina and intestine differ by more than an order of magnitude in exposure time, so a single systemic dose is the wrong shape of intervention. Handwave Whether such a reset would preserve the individual in the nervous system is unanswered and, on present methods, unasked; it is the point at which this brief stops being biology and becomes the identity question that Brain Preservation asks from the opposite direction.

• Depends on Depends first on an endpoint that means something: a demonstration that epigenetic-clock deltas predict within-individual function and mortality. That is a cohort study in existing biobank data, it is cheap, no reprogramming laboratory is positioned to run it, and until it exists every result in this brief can be read two ways. Depends second on delivery — tissue-restricted, dose-controlled, switchable expression at therapeutic dose in a large animal, matching the tolerance profile the mouse work already mapped, where retina takes ten to eighteen months of continuous exposure and intestine takes days. Depends third on removing the inducible transgene, since a doxycycline-responsive cassette is an experimental construct and not a medicine. The second and third arrive from gene therapy and mRNA delivery generally rather than from this field, which is why the binding constraint is expected to migrate from biology to industry rather than the other way.
• Requires (not on this map) Two institutional constraints bind harder than any bench result. There is no endpoint a regulator will accept for rejuvenation, so the only trials available are for organ-specific indications, and the field's chosen framing puts it behind a door that has never opened. And because epigenetic age is already a consumer product while the intervention is not, the first credible human result will create a clinic market faster than any evidence base can be assembled — the young-plasma episode is the precedent, and nothing in the present rules would slow the repeat.
• Enables Enables organ-specific functional restoration well before it enables anything about lifespan: the retinal result is the template, and axon regeneration after injury, corneal and wound healing, and immune rejuvenation are the plausible near-term products, each with a defined patient population and a measurable endpoint. Enables, if the information-loss hypothesis survives testing, a general reframing of ageing as a recoverable state rather than accumulated damage — which would change what every other longevity programme is trying to do, and would give regeneration and cancer biology a result they currently lack: evidence that a differentiated cell holds an addressable record of its own earlier state. Enables, less happily, a consumer market in age scores and interventions to move them, well ahead of any evidence that moving them helps.
• Adjacent Sits alongside senolytics, rapamycin-class geroprotectors and plasma dilution as one of four modalities competing to be the thing that works, and shares one instrument with all of them: the epigenetic clock, so a single unresolved validity question sits underneath four fields at once. Shares the cluster's regulatory blocker, since ageing is not a recognised indication for any of them. Shares delivery technology with gene therapy and nanomedicine, stratification with precision medicine, and controlled dedifferentiation with limb and whole-organ regeneration, which want the same biology for a different purpose. And with brain preservation it shares the unresolved question of how much of a person is molecular state rather than structure — which decides whether a nervous system can be reset at all.

Established “Partial reprogramming doubled the lifespan of old mice.” This is the single largest distortion in the subject, and it is a factor-of-fifteen error. The source reports a 109% increase in median remaining life in mice that were already 124 weeks old at treatment: controls had 8.86 weeks of median life remaining, treated animals 18.5 weeks. Established Do the arithmetic on total lifespan: 133 weeks becomes about 142.5 weeks, a gain of roughly 9.5 weeks, about 7%. Established The paper states its figure correctly and the error is entirely downstream, in the restatement of a conditional quantity — remaining life at extreme old age — as an unconditional one. Frontier The comparison that shows how large the distortion is: 109% against 7% is a factor of about 15, and 7% is less than the 9 to 14% rapamycin produced in 2009 when fed from 600 days of age, and less than the 13% a single dose of telomerase gene therapy produced in two-year-old mice in 2012. Nothing in the position section of this brief leans on the 109% figure and nothing should.

Established “Reprogramming has been shown to extend lifespan in normal mice.” The 2016 lifespan result is in LAKI progeroid animals, a model of accelerated ageing rather than of ageing. Established The 2022 long-duration study, which did use normally-ageing mice, reports no lifespan endpoint at all — its claims are molecular, physiological and about safety. Frontier The only normal-mouse lifespan claim in the record is the one with the denominator problem above, from a preprint that does not state the lifespan cohort's sample size.

Established “Yamanaka factors have reversed human ageing by thirty years.” The thirty-year figure comes from fibroblasts in culture from three donors, aged 38, 53 and 53, measured on an epigenetic clock and a transcriptome clock, with telomeres unchanged and the authors unable to exclude residual pluripotent-like cells. Established No human being has been treated with a reprogramming therapy.

Established “Epigenetic age is biological age.” Horvath's paper states the clock does not measure mitotic age or cellular senescence, and it was trained to predict chronological age, which it does with a median error of 3.6 years. Frontier The field's own 2024 review states that clock reversal and rejuvenation should not be used interchangeably because the causal relationship is undetermined. Speculative The strongest form of the sceptical case — the clocks-are-a-mirage argument — is worth stating properly, because it is held inside the field and not by cranks: a 353-site elastic-net regression fit to chronological age will, by construction, select sites whose methylation changes monotonically with time; an intervention that perturbs the methylation machinery can move those sites without touching whatever causes an old animal to be frail; and the one case where clock and a known ageing axis were measured together, telomeres did not follow. Frontier The counter-argument is TET1/TET2 dependence: if resetting were a generic wipe, it would not require the specific enzymes that perform targeted demethylation. That is a real answer, and it is not yet a demonstration that the clock reads biology.

Established “Myc was dropped from the cocktail because it was the dangerous one.” Myc was omitted from the OSK protocols and it is indeed an oncogene, but the teratoma data point elsewhere: two-copy OSKM mice developed teratomas and single-copy mice developed none, and continuous OSK in retina ran 10 to 18 months without tumours while continuous expression in liver and intestine was lethal. Established Dose and tissue dominate; removing Myc is not what makes it safe.

Established “Chemical reprogramming means we will be able to take a pill.” The cocktails are in vitro only, the primary readout is a proprietary fluorescence reporter, the paper contains no animal data, and its authors state that safety must be tested in mammalian models before human trials. Established The disclosure attached to that paper lists consulting roles, board memberships, investments and a provisional patent held by three of the authors.

Established “Reprogramming causes cancer, so it can never be a therapy.” This is the sceptic-side error and it overstates in the other direction. Teratoma formation is dose- and tissue-dependent: single-copy cyclic induction produced none, retinal OSK ran 10 to 18 months without any, and the AAV lifespan study reported none. Frontier The risk is real, it is the reason the therapeutic window is narrow, and it is manageable in principle by restricting cell type and dose — which is exactly what the most successful experiment in the field did.

Established “Altos Labs is trying to make people immortal.” Its own president describes the target as healthspan, with longevity extension an accidental consequence — a framing more cautious than most of the coverage it received. Speculative “The rejuvenation effect is permanent.” Persistence after treatment ends is on the field's own list of open questions and no decay curve has been published; the honest statement is that nobody knows whether the effect lasts a month or a lifetime. Handwave “Young blood rejuvenates old animals, and reprogramming is the sophisticated version of the same idea.” The best-designed experiment in that adjacent area replaced old plasma with saline and albumin — containing nothing young at all — and met or exceeded heterochronic blood sharing, which points at dilution of age-elevated factors rather than transfer of youthful ones. The two mechanisms have nothing in common except the word rejuvenation.